Merck's Cordaptive: Just Another Cholesterol Combo, or More?
Executive Summary
At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
You may also be interested in...
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
Merck Taking Aggressive Approach To Cardiovascular Development
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program